A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2379 in Normal Healthy Male Volunteers

Summary

The main purpose of this study is to assess the safety and pharmacokinetics of SRT2379 (25,
75, 250, 500, 1000, 2000, and 3000 mg/day [fasted] and 500 mg/day [fed]) in healthy male
volunteers.

The purpose is also to explore the effect of SRT2379 on plasma concentrations of Fibroblast
Growth Factor 21 (FGF21) and to identify other possible biomarkers suitable for future
clinical assessment of oral SIRT1 activators.

Description

Prospective, single center, clinical study of SRT2379 administered orally. Randomized,
placebo-controlled, single-blind, multiple-dose, dose-escalation inpatient/outpatient study
to assess the safety and pharmacokinetics (PK) of SRT2379 in healthy male volunteers.
Approximately sixty-four (64) subjects aged 18-55, who fulfill the inclusion/exclusion
criteria, will be enrolled in this study. Eight cohorts of eight subjects each will be
examined. Subjects within each cohort will be randomized 6:2 to receive SRT2379 at one of
seven escalating doses (A, B, C, D, E, F or G), likely to be 25, 75, 250, 500, 1000, 2000,
and 3000 mg/day or placebo. All cohorts will be administered SRT2379 in the fasted state,
with the exception of one cohort that will receive one of the stated doses of SRT2379 in the
fed state (the dose of SRT2379 administered to subjects in the fed state is planned to be
500 mg, however this may be modified upwards or downwards following evaluation of safety and
pharmacokinetic data from earlier cohorts. The fed cohort will be the final cohort dosed in
the study.). Two subjects will be dosed on Day 1 of the single dose period with one subject
receiving active treatment and one subject receiving placebo. The remainder of subjects
within each cohort will be dosed on Day 2 of the single dose period with five subjects
receiving active treatment and one subject receiving placebo, assuming that no safety issues
arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test
material for all dosing days in the study.

Each cohort of subjects will be dosed sequentially approximately three weeks apart for the
single dose period, and return to the study unit approximately two weeks after their single
dose administration to receive 7 consecutive days of dosing for the multiple-dose period.
Each cohort of subjects in the multiple-dose period will be dosed sequentially,
approximately, two weeks apart (from multiple dose period Day 7 of preceding cohort to
multiple dose period Day 1 dose of the subsequent cohort), allowing for a comprehensive
safety assessment prior to initiation of an escalated dose in a subsequent cohort.

Subjects will sign the informed consent form at the Screening Visit. If eligible and
willing to participate, subjects will enter into the study. Subjects will have fasted for
at least 10 hours overnight and be randomized to receive SRT2379 or placebo (test material).
The subject cohort assigned to the fed dose will consume a standardized meal before
receiving test material; all other subjects will receive test material in a fasted state.
Subjects will be required to stay overnight at the study unit for two nights during the
single dose period of the study and subsequently, for the duration of the seven-day
multiple-dose period (8 consecutive overnight stays) to assess safety and to gather required
PK samples. Subjects will be asked to return to the study center for an End of Study
safety assessment approximately 1 week after the last administration of study drug during
the multiple-dose period.

Atherosclerotic cardiovascular disease is the leading cause of mortality of patients with type 2 diabetes mellitus, and both coronary artery disease (CAD) and diabetes mellitus are associated with inf...

Patients with Diabetes Mellitus (DM) are required to have long-term treatment regimen and strict self-management, which thus might lead to the Diabetes Distress (DD). Patients' DD varies in different ...

Medical and Biotech [MESH] Definitions

Diabetes Mellitus, Type 2

A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.

Prediabetic State

The time period before the development of symptomatic diabetes. For example, certain risk factors can be observed in subjects who subsequently develop INSULIN RESISTANCE as in type 2 diabetes (DIABETES MELLITUS, TYPE 2).

Diabetes Mellitus, Type 1

A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.

Diabetes Mellitus, Lipoatrophic

A type of diabetes mellitus that is characterized by severe INSULIN RESISTANCE and LIPODYSTROPHY. The latter may be generalized, partial, acquired, or congenital (LIPODYSTROPHY, CONGENITAL GENERALIZED).

Diabetic Ketoacidosis

A life-threatening complication of diabetes mellitus, primarily of TYPE 1 DIABETES MELLITUS with severe INSULIN deficiency and extreme HYPERGLYCEMIA. It is characterized by excessive LIPOLYSIS, oxidation of FATTY ACIDS, production of KETONE BODIES, a sweet smell to the breath (KETOSIS;) DEHYDRATION; and depressed consciousness leading to COMA.

More From BioPortfolio on "A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2379 in Normal Healthy Male Volunteers"

Relevant Topics

NutritionWithin medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

BloodBlood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells. In vertebrates, it is composed of blo...

PharmacyPharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs.
The scope of...